Sarangi Aditya Narayan, Goel Amit, Singh Ankur, Sasi Avani, Aggarwal Rakesh
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226014, India.
Biomedical Informatics Center, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
BMC Gastroenterol. 2017 Nov 28;17(1):125. doi: 10.1186/s12876-017-0683-9.
Gut microbiota may be altered in patients with cirrhosis, and may further change after administration of lactulose. We studied the composition of gut microbiota in patients with cirrhosis and assessed the effect on it of lactulose administration.
Stool specimens were collected from 35 patients with cirrhosis (male 26; median [range] age: 42 [29-65] years) and 18 healthy controls (male 14; 44.5 [24-67] years); 21 patients provided another specimen after lactulose administration for 55 [42-77] days. For each, a DNA library of V3 region of bacterial 16S ribosomal RNA was subjected to paired-end Illumina sequencing. Inter-specimen relationship was studied using principal co-ordinate analysis. Abundances of various bacterial taxa, and indices of alpha and beta diversity were compared, between patients and controls, and between specimens collected before and after lactulose.
Gut microbiota from cirrhosis patients and controls showed differential clustering, and microbiota from patients with cirrhosis had less marked alpha diversity. Abundances of dominant phyla (Bacteroidetes, Firmicutes and Proteobacteria) were similar. However, patients with cirrhosis had lower abundances of five phyla, namely Tenericutes, Cyanobacteria, Spirochaetes, Elusimicrobia and Lentisphaerae, and differences in abundances of several families and genera than in controls. Lactulose administration did not lead to any change in alpha and beta diversities, species richness and abundances of various bacterial taxa in gut microbiota.
Gut microbiota in cirrhosis differ from healthy persons and do not change following lactulose administration. The latter suggests that the effect of lactulose on hepatic encephalopathy may not be related to alteration in gut microbiota.
肝硬化患者的肠道微生物群可能会发生改变，并且在服用乳果糖后可能会进一步变化。我们研究了肝硬化患者肠道微生物群的组成，并评估了乳果糖给药对其的影响。
收集了35例肝硬化患者（男性26例；年龄中位数[范围]：42[29 - 65]岁）和18名健康对照者（男性14例；44.5[24 - 67]岁）的粪便标本；21例患者在服用乳果糖55[42 - 77]天后提供了另一份标本。对每份标本，细菌16S核糖体RNA V3区域的DNA文库进行双端Illumina测序。使用主坐标分析研究样本间的关系。比较了患者与对照者之间以及乳果糖服用前后采集的标本之间各种细菌类群的丰度以及α和β多样性指数。
肝硬化患者和对照者的肠道微生物群显示出不同的聚类，肝硬化患者的微生物群α多样性较低。优势菌门（拟杆菌门、厚壁菌门和变形菌门）的丰度相似。然而，肝硬化患者的五个菌门，即柔膜菌门、蓝细菌门、螺旋体门、迷踪菌门和浮霉菌门的丰度较低，并且几个科和属的丰度与对照者相比存在差异。服用乳果糖并未导致肠道微生物群的α和β多样性、物种丰富度以及各种细菌类群的丰度发生任何变化。
肝硬化患者的肠道微生物群与健康人不同，并且服用乳果糖后不会改变。后者表明乳果糖对肝性脑病的作用可能与肠道微生物群的改变无关。
